Ready for Answers?

If you suspect your patient may have an autoimmune disease, the Isolate test panels will be available beginning in July 2017. IsolateMS is now available. IsolateIBS-IBD will be available in the fall of this year, and IsolateFibromyalgia by the end of the year.

Review our peer-reviewed research and join our community to stay up-to-date on our progress.

Join our Community

Diagnose Faster. Treat Sooner. Improve Lives.

At IQuity, our goals are clear:

  • Enable providers optimally diagnose and treat disease at the earliest stage possible
  • Lower the overall cost of life-long autoimmune illnesses
  • Minimize patient uncertainty and fear often associated with traditional, protracted testing methodologies

We’ve focused on solving the autoimmune diagnostic challenge for more than a decade. And, our breakthrough RNA analytic process, IQIsolate, gives providers a new tool to confirm a suspected diagnosis, with accuracy greater than 90%, and help patients at the earliest sign of symptoms.

More on our technology

RNA Unlocks the Code

Autoimmune patients exhibit distinct RNA expression patterns in their blood that distinguish them from patients whose symptoms mimic, but are not autoimmune based.

Accurate Results

IQuity’s process, IQIsolate, is a suite of algorithms that delivers information for providers to confirm a suspected autoimmune diagnosis with greater than 90% accuracy – in as little as 7 days.

Improved Outcomes

Studies confirm that diagnosing patients early and treating sooner leads to improved care, enhanced patient satisfaction and better long-term outcomes.

The Value of IQIsolate Test Panels
Early. Accurate. Fast.

  • Diagnosing autoimmune diseases and related conditions can be challenging, often taking months or years. The ability to know within a week if patients are battling a specific condition gives providers the information to initiate effective treatment earlier than current methods.
  • IQIsolate powers the Isolate test panels that exhibit greater than 90% accuracy in identifying gene expression patterns consistent with a specific disease at the earliest onset of symptoms.
  • IQuity's research has focused on three medical specialties: neurology, gastroenterology and rheumatology which cover the majority of patients suffering from autoimmune disease and related disorders.
  • Beginning treatment at the earliest stages of disease leads to the best long-term outcomes by minimizing the debilitating effects of these chronic conditions.
  • IQIsolate utilizes RNA-expression data, which provides real-time information from the immune cells found in blood. RNA is often a faster indicator of disease than conventional methods that measure damage to organs and tissues over time.



The IQIsolate process represents a breakthrough in helping providers confirm suspected diagnoses of complex autoimmune diseases and related conditions.

Whether you are seeing a patient who presents with symptoms for the first time or treating a patient following a referral, IQuity’s Isolate tests give you information to confirm a suspected diagnosis, determine any additional diagnostic work-up needed, and initiate treatment at the earliest onset of the disease.

Internists & Primary Care

Primary Care and Internal Medicine providers are often the first to see patients who present with a suspected autoimmune disease or related condition. 

When you suspect that a patient’s symptoms may indicate an autoimmune disease or related condition like multiple sclerosis, IBS, Crohn's, ulcerative colitis, rheumatoid arthritis, lupus or fibromyalgia, IQuity’s breakthrough RNA technology, IQIsolate, powers test panels that provide a Yes or No result in as little as 7 days (conventional testing processes often can take months to years to confirm a diagnosis).

Now referrals to specialists can be accompanied with a test result that is more than 90% accurate.

Peer-Reviewed Articles

Identification of Molecular Biomarkers for Multiple Sclerosis

Quantitative real-time polymerase chain reaction analysis was used to identify a minimum number of genes of which transcript levels discriminated multiple sclerosis patients from patients with other chronic diseases and from controls.

Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis

Results indicate that gene-expression differences in blood accurately exclude or include a diagnosis of MS and suggest that these approaches may provide clinically useful prediction of MS.

Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis

Using machine learning techniques, including support vector machines, this study demonstrates that gene expression signatures can accurately identify subjects with a clinically isolated syndrome who later progress to multiple sclerosis.